The FDA has approved guselkumab (Tremfya, J&J) as the first IL-23 inhibitor available in both subcutaneous (SC) and IV induction regimens for moderate to severe ulcerative colitis. Results from the phase 3 ASTRO trial showed significant improvements in remission and endoscopic outcomes with SC dosing, comparable to IV induction. Experts note the SC route could ease barriers by enabling self-administration and reducing infusion burdens.
Keep Reading
Add A Comment